Mean DLQI score was 5.2 for all respondents, which falls within the range of previously reported values in populations that included all severities of rosacea, writes Baldwin et al. For patients with severe, moderate and mild erythema, mean DLQI scores were 13.4, 5.7 and 3.8, respectively (P <0.0001). Approximately two-thirds of respondents with severe erythema had total DLQI scores indicating very large or extremely large effects of rosacea on their HRQoL.
"The more severe the erythema," Dr. Baldwin says, "the more significantly patients were impacted."
In fact, the survey showed that the quality-of-life impact of rosacea-associated erythema was comparable to that of eczema, atopic dermatitis or psoriasis.
The survey's purpose was to encourage doctors to consider proactively discussing the impact of rosacea on patients' lives.
"The study reminds us as physicians that when a patient walks in for another diagnosis and you see that they have centrofacial redness, it shouldn’t be ignored," she says.
In a busy dermatologists's office, says Dr. Baldwin, whether a doctor proactively mentions the erythema often depends on how busy the office is at the moment. If a patient's appointment time is nearly up, she says, dermatologists might suggest discussing erythema, which can be a time-consuming endeavor, on the patient's next visit. She also suggests asking how much the redness bothers patients and mentioning that new medications, as well as lasers and light treatments, can significantly improve rosacea. Additional tools that might encourage proactive discussions include waiting-room literature, CCTV programming and intake forms that ask specifically about rosacea, Dr. Baldwin says.